Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 20 of 95, showing 5 Applications out of 474 total, starting on record 96, ending on 100

# Protocol No Study Title Investigator(s) & Site(s)

96.

ECCT/23/02/01   Hibiscus Kid\'s Study
    A Single Arm, Open Label, Phase 1/2 Study to Evaluate the Pharmacokinetics and Safety of Etavopivat in Pediatric Patients with Sickle Cell Disease   
Principal Investigator(s)
1. Videlis Nduba
2. Walter Otieno
3. Isaac Tsikhutsu
Site(s) in Kenya
1. AHERO CLINICAL TRIALS UNIT (Kisumu county)
2. KEMRI-Walter Reed-Kericho (Kericho county)
3. KEMRI: Siaya Clinical Research Annexe (Kisumu county)
4. Kombewa Clinical Research Centre (Kisumu county)
 
View

97.

ECCT/23/01/08   SKY-06
    A PHASE II/III, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF TIRAGOLUMAB IN COMBINATION WITH ATEZOLIZUMAB PLUS   PEMETREXED AND CARBOPLATIN/CISPLATIN VERSUS PEMBROLIZUMAB PLUS PEMETREXED AND CARBOPLATIN/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NON-SMALL-CELL LUNG CANCER   
Principal Investigator(s)
1. Fredrick Chite Asirwa
Site(s) in Kenya
International Cancer Institute
 
View

98.

ECCT/23/01/06   FENHANCE
    A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS         CSF BIOMARKER SUBSTUDY ASSOCIATED WITH A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY (GN41851) TO EVALUATE THE EFFICACY AND SAFETY OF FENEBRUTINIB COMPARED WITH TERIFLUNOMIDE IN ADULT PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS        
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
View

99.

ECCT/23/01/05   IMPALA Study
    Efficacy, Safety and Effectiveness of Injectable Cabotegravir/Rilpivirine in Improving HIV-1 Control in Sub-Saharan Africa: A Pragmatic Phase 3b Open-Label Randomized Controlled Trial   
Principal Investigator(s)
1. Loice Achieng Ombajo
Site(s) in Kenya
1. Kenyatta National Hospital (Nairobi City county)
2. Jaramogi Oginga Odinga Teaching and Referral Hospital (Kisumu county)
 
View

100.

ECCT/23/01/04   ACTIV-2d/A5407
    A Phase 3, multicenter, randomized, double-blind, 24-week study of the clinical and antiviral effect of S-217622 compared with placebo in non-hospitalized participants with COVID-19   
Principal Investigator(s)
1. Lucas Tina Otieno
Site(s) in Kenya
1. MOI UNIVERSITY CLINICAL RESEARCH CENTRE (Uasin Gishu county)
2. Victoria Biomedical Research Institute, (Kisumu county)
3. Kenya Medical Research Institute/Walter Reed Project (Kericho county)
4. Kenyatta National Hospital (Nairobi City county)
5. Ahero Clinical Trials Unit, (Kisumu county)
6. KEMRI CCR – BUTERE SITE (Kakamega county)
 
View